When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Minnesota Attorney General Keith Ellison is expected to announce a "major development" in the litigation against three large ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

The general mood among these heavyweight investors is divided, with 36% leaning bullish and 42% bearish. Among these notable ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

DETROIT, MI, UNITED STATES, January 13, 2025 /EINPresswire / -- The National Veteran Business Development Council (NVBDC) is excited to announce an exclusive webinar featuring Eli Lilly and Company ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...